Amyloid-β Specific Regulatory T Cells to Treat Alzheimer’s Disease
T cells of the adaptive immune system have been engineered to target amyloid-β, a protein associated with the onset of Alzheimer’s disease. In animal studies, these engineered regulatory T cells successfully reduced the pathology of Alzheimer’s disease by dampening inflammatory responses in the brain. This approach holds promise for potential therapeutic targeting of neurodegenerative conditions.
Researchers have conferred amyloid-β antigen specificity to regulatory T cells by engineering the T cell receptor (TCR) specific for amyloid-β. The adoptive transfer of these engineered T cells led to sustained immune suppression, reduced microglial reaction, and decreased amyloid loads in the brain. This reduction in amyloid load was associated with improved cognitive functions.
For more information, please visit the following link: Link: https://doi.org/10.1186/s13024-023-00692-7
